DexCom

Youtube Subscribe

Open: 123.59 Close: 124.46 Change: 0.87

Our AI found 15 flaws in DexCom.

Are looking for the most relevant information about DexCom? Investor spend a lot of time searching for information to make investment decisions in DexCom. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about DexCom are: Dexcom, insulin, Stelo, CGM, sensor, G7, pump, and the most common words in the summary are: dexcom, g7, diabetes, cgm, glucose, g6, stock, . One of the sentences in the summary was: Average price target for DexCom is $133.94, which is 7.62% higher than the current …

Concept Map

Semantic Network

Stock Summary

DexCom, Inc. focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. The company provides its systems for use by people with diabetes, as well as for use. Dexcom G6.

Today's Summary

Dexcom submitted its new glucose sensor, Stelo, to the FDA for approval in the fourth quarter of 2023. Average price target for DexCom is $133.94, which is 7.62% higher than the current price. Dexcom does not appear to pay any dividends.

Today's News

Dexcoms Stelo CGM is is a health tech gadget with purpose. The Stelo is meant to give Type 2 diabetics who dont need insulin a more affordable way to monitor their blood sugar. Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The integration of Dexcom CGM with Tandems insulin pump represents a significant advancement. Dexcom G7 is a CGM system that is now connected with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The combination of Dexcom. G7 with the. t: slim X 2 insulin pump offers the fastest sensor warmup time and industry-leading remote monitoring capabilities. Dexcom G7 Continuous Glucose Monitoring System now available in Canada. Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and South Africa. Dexcom announced it had submitted an application to the US FDA during Q4 2023 for a new glucose sensor: Stelo. A glucose sensor developed for people with type 2 diabetes who do not use insulin, Dexcom expects to launch the product in Summer 2024. Dexcom G6 sensor was reading 69 and in actuality my blood glucose was 481. Dexcom does not return phone calls, lies about shipping and knowledge of the product is poor. Customer support is AWFUL, Dexcom. Dexcom has filed 1309 patents. Dexcom and Abbott are competing manufacturers. Dexcoms Stelo is a glucose monitor for Type 2 diabetics who dont use insulin. Rather than a CGM that only works to monitor and alert users about dangerously high/low blood sugar, the Stelo will give those with Type 2 insights into how their diet, exercise, sleep, or stress affects levels. Dexcom submitted its new glucose sensor, Stelo, to the FDA for approval in the fourth quarter of 2023. Dexcoms final, audited fiscal results for 2023 will be released on February 8, 2024. Manufacturer Coupon Save $200 on both sensors and transmitters. Manufacturer coupon for uninsured patients may pay as little as $181.64. Average price target for DexCom is $133.94, which is 7.62% higher than the current price. DexCom does not appear to pay any dividends at this time. DexCom, Inc.s (NASDAQ:DXCM) P/S Still Appears To Be Reasonable. When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios below 3.2x. The GripShield barrier forms a protective barrier between your skin and Dexcom adhesive, minimizing potential skin irritations.

Stock Profile

"DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California."

Keywords

The game is changing. There is a new strategy to evaluate DexCom fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about DexCom are: Dexcom, insulin, Stelo, CGM, sensor, G7, pump, and the most common words in the summary are: dexcom, g7, diabetes, cgm, glucose, g6, stock, . One of the sentences in the summary was: Average price target for DexCom is $133.94, which is 7.62% higher than the current price. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #dexcom #g7 #diabetes #cgm #glucose #g6 #stock.

Read more →

Youtube Subscribe

---